Health TidingsOno Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Ono Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Read Post »
Health TidingsAtara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Atara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Read Post »
Health TidingsFDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... FDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... Read Post »
Health TidingsPhase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Phase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Read Post »
Health TidingsIntellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Intellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Read Post »
Health TidingsJohnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Johnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Read Post »
Health TidingsHuntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Huntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Read Post »
Health TidingsRoche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Roche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Read Post »
Health TidingsFDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... FDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... Read Post »
Health TidingsOno Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Ono Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Read Post »
Health TidingsFDA Grants Priority Review to Ionis’ Olezarsen for Severe Hypertrigly... FDA Grants Priority Review to Ionis’ Olezarsen for Severe Hypertrigly... Read Post »
Health TidingsEMA CHMP Backs Moderna’s mCOMBRIAX®: Pioneering Flu-COVID Combo Vacc... EMA CHMP Backs Moderna’s mCOMBRIAX®: Pioneering Flu-COVID Combo Vacc... Read Post »
Health Tidings Policy & AcquisitionsNovartis Finalizes $12B Avidity Buyout for AOC Muscle Tech Novartis Finalizes $12B Avidity Buyout for AOC Muscle Tech Read Post »
Health Tidings Policy & AcquisitionsEarendil Labs Secures $885M WuXiTecan-2 Rights from WuXi XDC Earendil Labs Secures $885M WuXiTecan-2 Rights from WuXi XDC Read Post »
Health TidingsCHMP Backs Single-Dose Acoziborole to End Gambiense Sleeping Sickness Era CHMP Backs Single-Dose Acoziborole to End Gambiense Sleeping Sickness Era Read Post »
Health Tidings Policy & AcquisitionsExclusive: Boehringer Ingelheim Acquires Sitryx Program in High-Value Autoi... Exclusive: Boehringer Ingelheim Acquires Sitryx Program in High-Value Autoi... Read Post »
Health TidingsGilead’s Bictegravir/Lenacapavir FDC Shows Week 48 Promise in ARTISTR... Gilead’s Bictegravir/Lenacapavir FDC Shows Week 48 Promise in ARTISTR... Read Post »
Health TidingsViiV Healthcare Unveils Promising Phase 1 Data for Two Ultra Long-Acting HI... ViiV Healthcare Unveils Promising Phase 1 Data for Two Ultra Long-Acting HI... Read Post »
Health TidingsGSK’s Bepirovirsen NDA Accepted in Japan for Chronic Hepatitis B GSK’s Bepirovirsen NDA Accepted in Japan for Chronic Hepatitis B Read Post »
Health TidingsGSK’s Linerixibat Gains NMPA Priority Review in China for Itch in Rar... GSK’s Linerixibat Gains NMPA Priority Review in China for Itch in Rar... Read Post »
Health Tidings Policy & AcquisitionsBeam Therapeutics Advances BEAM-304 for PKU and Pfizer Collaboration Beam Therapeutics Advances BEAM-304 for PKU and Pfizer Collaboration Read Post »
Health Tidings Policy & AcquisitionsNovo Nordisk Partners with Vivtex to Pioneer Oral Biologics for Obesity and... Novo Nordisk Partners with Vivtex to Pioneer Oral Biologics for Obesity and... Read Post »
Health Tidings Policy & AcquisitionsGSK Acquires 35Pharma for $950M to Advance HS235 in Pulmonary Hypertension ... GSK Acquires 35Pharma for $950M to Advance HS235 in Pulmonary Hypertension ... Read Post »
Health TidingsViatris Phentolamine Drops Advance to FDA Review for Presbyopia Treatment Viatris Phentolamine Drops Advance to FDA Review for Presbyopia Treatment Read Post »
Health TidingsOno Expands Opdivo® Reach: New Korean Approval for MSI-High CRC Ono Expands Opdivo® Reach: New Korean Approval for MSI-High CRC Read Post »
Health Tidings Policy & AcquisitionsAstellas and Vir Biotechnology Unite to Advance VIR-5500, a Next-Gen T-Cell... Astellas and Vir Biotechnology Unite to Advance VIR-5500, a Next-Gen T-Cell... Read Post »
Health TidingsTeva/Medincell Advance: SOLARIS-Backed TEV-‘749 NDA Accepted by FDA Teva/Medincell Advance: SOLARIS-Backed TEV-‘749 NDA Accepted by FDA Read Post »
Health TidingsNovo Nordisk Slashes List Prices of Wegovy, Ozempic, and Rybelsus by Up to ... Novo Nordisk Slashes List Prices of Wegovy, Ozempic, and Rybelsus by Up to ... Read Post »
Health Tidings Policy & AcquisitionsOrganon Licenses MIUDELLA®: New Hormone-Free Copper IUD Option Organon Licenses MIUDELLA®: New Hormone-Free Copper IUD Option Read Post »
Health TidingsFlexible SC Amivantamab Regimens Now Authorized EU-Wide for EGFR-Mutant Lun... Flexible SC Amivantamab Regimens Now Authorized EU-Wide for EGFR-Mutant Lun... Read Post »
Health TidingsUltragenyx Scores FDA Priority Review for DTX401 in Rare Metabolic Disorder Ultragenyx Scores FDA Priority Review for DTX401 in Rare Metabolic Disorder Read Post »
Health TidingsEMA Validates ENHERTU® for Post-Neoadjuvant HER2+ Breast Cancer EMA Validates ENHERTU® for Post-Neoadjuvant HER2+ Breast Cancer Read Post »
Health TidingsSetback for Corcept as Court Backs Teva in Korlym Generic Fight Setback for Corcept as Court Backs Teva in Korlym Generic Fight Read Post »
Health TidingsRoche’s Giredestrant NDA Accepted by FDA for ESR1-Mutated Breast Canc... Roche’s Giredestrant NDA Accepted by FDA for ESR1-Mutated Breast Canc... Read Post »
Health TidingsSavara’s MOLBREEVI BLA Accepted by FDA with Priority Review for Rare ... Savara’s MOLBREEVI BLA Accepted by FDA with Priority Review for Rare ... Read Post »
Health TidingsOne High-Quality Trial, Not Two: what the FDA changed and what it means One High-Quality Trial, Not Two: what the FDA changed and what it means Read Post »
Health TidingsOutlook Therapeutics Partners with Mediconsult for Exclusive LYTENAVA™ Di... Outlook Therapeutics Partners with Mediconsult for Exclusive LYTENAVA™ Di... Read Post »
Health TidingsChugai Launches ELEVIDYS in Japan for Duchenne Muscular Dystrophy Chugai Launches ELEVIDYS in Japan for Duchenne Muscular Dystrophy Read Post »
Health TidingsRYBREVANT FASPRO™ Shines in First-Line HNSCC with 56% Response Rate RYBREVANT FASPRO™ Shines in First-Line HNSCC with 56% Response Rate Read Post »
Health TidingsOmvoh Sets New IBD Standard: 3-Year Data + Lilly’s Combination Pipeli... Omvoh Sets New IBD Standard: 3-Year Data + Lilly’s Combination Pipeli... Read Post »
Health TidingsBoehringer Ingelheim Teams Up with NIPER Raebareli for Pharma Research Boos... Boehringer Ingelheim Teams Up with NIPER Raebareli for Pharma Research Boos... Read Post »
Health TidingsFDA Grants Priority Review to Garetosmab for Rare Bone Disorder FOP FDA Grants Priority Review to Garetosmab for Rare Bone Disorder FOP Read Post »
Health Tidings Policy & AcquisitionsNovartis Licenses UNP’s Macrocyclic Peptides in $1.8B CVD Collaborati... Novartis Licenses UNP’s Macrocyclic Peptides in $1.8B CVD Collaborati... Read Post »
Health TidingsJanux Therapeutics Dosed First Patient in JANX011 Study Janux Therapeutics Dosed First Patient in JANX011 Study Read Post »
Health TidingsRTF Resolved: Moderna’s Vaccine mRNA-1010 Advances to FDA Review RTF Resolved: Moderna’s Vaccine mRNA-1010 Advances to FDA Review Read Post »
Health TidingsFDA Accepts BMS’s NDA for Iberdomide in RRMM FDA Accepts BMS’s NDA for Iberdomide in RRMM Read Post »
Health TidingsEli Lilly’s TOGETHER-PsO Trial: Taltz Plus Zepbound Delivers Superior... Eli Lilly’s TOGETHER-PsO Trial: Taltz Plus Zepbound Delivers Superior... Read Post »
Health TidingsCompass Pathways Achieves Breakthrough in Phase 3 Trial for Psilocybin-Base... Compass Pathways Achieves Breakthrough in Phase 3 Trial for Psilocybin-Base... Read Post »
Health TidingsGSK RSV Vaccine Shows 75.6% Effectiveness Against Hospitalizations in Real-... GSK RSV Vaccine Shows 75.6% Effectiveness Against Hospitalizations in Real-... Read Post »
Health Tidings Policy & AcquisitionsKidswell Bio and Treehill Launch Kidswell USA to Advance Cell Therapy for C... Kidswell Bio and Treehill Launch Kidswell USA to Advance Cell Therapy for C... Read Post »
